查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070219

全球 VISTA 抑制劑市場：市場機會與臨床試驗洞察（2026 年）

Global VISTA Inhibitor Market Opportunities & Clinical Trials Insight 2026
出版日期: | 出版商: KuicK Research | 英文 80 Pages | 商品交期: 最快1-2個工作天內

價格

「全球VISTA抑制劑市場—市場機會和臨床試驗洞察（2026）」報告的主要發現和要點：

  • 調查方法
  • 首個 VISTA 抑制劑預計將於 2029 年獲得批准。
  • 依公司、國家、適應症和臨床試驗階段分析 VISTA 抑制劑臨床試驗。
  • 重點藥物臨床試驗啟動和完成時間表概述
  • VISTA標靶治療的區域性與適應症特異性創新趨勢
  • 全球VISTA抑制劑市場趨勢、發展及競爭格局

VISTA標靶治療的必要性及本報告的意義

VISTA抑制劑的全球市場在腫瘤免疫學領域具有巨大的潛力，這主要是由於需要克服現有查核點療法的抗藥性。 VISTA（V結構域Ig T細胞活化抑制劑）是一種新型免疫調節蛋白，能夠抑制T細胞的免疫活性並改變腫瘤微環境。與CTLA-4和PD-1不同，VISTA在髓系細胞和某些免疫細胞上高表達，使其成為下一代癌症免疫療法中極具前景的新標靶。大多數對現有查核點療法無反應或最終出現抗藥性的患者都會出現抗藥性，而新興的VISTA抑制劑正是為了解決這個抗藥性問題而開發的。目前（截至2026年6月），尚無核准的VISTA抑制劑，但有多種正在進行臨床試驗。

本報告對全球VISTA抑制劑領域的科學進展、臨床進展、競爭格局和策略機會進行了全面分析，將成為生物製藥公司、生物技術組織、投資者、研究人員和其他相關人員的重要參考資料。

本報告中包含對臨床試驗的深入分析

VISTA抑制劑的臨床開發持續構成VISTA市場的基礎。目前的研究主要集中在腫瘤適應症，特別是晚期固體癌瘤，因為腫瘤微環境中的免疫抑制會顯著影響疾病進程。正在進行的臨床試驗正在評估VISTA抑制劑在多種癌症中的療效，包括非小細胞肺癌（NSCLC）、大腸直腸癌（CRC）、卵巢癌、頭頸癌和膀胱癌。其目標是評估抑制VISTA是否能夠增強身體對腫瘤的免疫攻擊，並最終提高患者的存活率。

推動 VISTA 研發的領導企業

VISTA標靶治療領域目前僅限於少數幾家創新生物製藥公司。 Aurigene Oncology和Curis憑藉CA-170的研發，在該領域處於領先地位。 CA-170是目前處於臨床試驗階段的、針對VISTA標靶治療的最先進的候選藥物。此藥進入後期研發階段，顯示人們對VISTA標靶治療的療效越來越有信心。

VISTA抑制劑領域的其他主要參與企業包括Hummingbird Bioscience、Kineta和PharmAbcine，以及許多學術研究團隊。 Hummingbird Bioscience尤其引人注目，其開發的HMBD-002是First-in-Class的抗VISTA中和抗體，也是目前唯一正在研究的IgG4同型抗VISTA抗體。策略合作、許可授權和研究合作正日益成為許多公司發展計畫中的重要組成部分，使它們能夠加速研發進程、擴大臨床試驗規模並增強其免疫腫瘤產品組合。

VISTA標靶療法的未來前景

未來對VISTA抑制劑療法的研究預計將著重於深入了解VISTA的生物學特性，並確定哪些患者群體對這些療法有反應。目前的研究旨在闡明VISTA作為一種新型共刺激和抑制性免疫查核點的作用，以及其作為患者療效預測指標的潛在作用，這有助於在未來的研究和治療中更精準地選擇患者。

除了癌症適應症外，預計研發工作將持續擴大VISTA標靶療法的治療應用範圍。由於VISTA在免疫系統中具有調節功能，目前正在研究其在自體免疫疾病和發炎性疾病中的調節作用。生物標記發現、轉化醫學、人工智慧驅動的藥物研發以及聯合免疫療法等方面的進一步進展，將加深對該標靶的理解，並為多種適應症的臨床治療帶來更多機會。

目錄

第1章：調查方法

第2章 VISTA：一種新的免疫查核點

  • 什麼是VISTA抑制？
  • VISTA 蛋白質結構與生物學
  • VISTA抑制劑的作用機制

第3章：VISTA 作為查核點

  • VISTA 作為抑制性免疫查核點
  • VISTA 作為協同刺激查核點
  • VISTA抑制劑與傳統免疫查核點抑制劑的比較

第4章：VISTA在疾病進展與治療的重要性

  • VISTA 在促進癌症進展中發揮作用。
  • VISTA作為一種潛在的癌症生物標記
  • VISTA 作為自體免疫疾病的治療標靶

第5章：全球VISTA抑制劑市場及臨床開發展望

  • 現狀
  • 未來機遇

第6章：VISTA標靶治療與臨床創新趨勢及適應症

  • 固體癌
  • 血癌
  • 自體免疫疾病與發炎性疾病

第7章：VISTA標靶治療與區域臨床創新趨勢

  • 美國
  • 歐洲
  • 印度
  • 澳洲

第8章：VISTA抑制劑全球臨床試驗概述

  • 愛別
  • 國家
  • 適應症
  • 按組織

第9章：VISTA抑制劑臨床試驗的全球概況（按公司、國家、適應症和階段分類）

  • 第一階段
  • 第一/二期
  • 第三階段

第10章：全球VISTA抑制劑市場動態

  • 市場促進因素
  • 市場挑戰

第11章 競爭格局

  • Aurigene Discovery Technologies
  • Curis
  • Hummingbird Bioscience
  • Kineta
  • PharmAbcine

Global VISTA Inhibitor Market Opportunities & Clinical Trials Insight 2026 Report Findings & Highlights:

  • Research Methodology
  • First VISTA Inhibitor Drug Approval By 2029
  • VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
  • Timeline Overview Of Clinical Study Initiation & Completion For Key Drugs
  • VISTA Targeted Therapies Innovation Trends By Region & Indication
  • Global VISTA Inhibitors Market Dynamics, Trends & Competitive Landscape

Need For VISTA Targeting Therapies & Why This Report?

The VISTA inhibitor market worldwide is showing substantial promise in the field of immuno-oncology, primarily because of the necessity to counteract resistance to current checkpoint therapies. VISTA, or V-domain Ig Suppressor of T-cell Activation, is a new type of immune regulatory protein which is responsible for dampening immune activity of T-cells and modifying the tumor microenvironment. Unlike CTLA-4 and PD-1, VISTA can be strongly expressed on myeloid cells and some immune cells, thereby creating a desirable new target in next-generation cancer immunotherapies. Resistance to current checkpoint therapy approaches, which occur in the majority of patients who either do not respond or later become refractory to treatment, are targeted by the emerging class of VISTA inhibitors. While no VISTA inhibitor is currently approved (as of June 2026), a handful are in the clinic.

This report offers a thorough analysis of the scientific advances, clinical progress, competitive activity and strategic opportunities within the worldwide VISTA inhibitor arena. It is an essential tool for biopharmaceutical companies, biotechnology organizations, investors, investigators and other interested parties.

Clinical Trials Insight Included In Report

Clinical development of the VISTA inhibitor continues to be the cornerstone of the VISTA market. The majority of current studies are targeted at oncology indications, specifically late stage solid tumors, where immune suppression at the tumor microenvironment drives the disease landscape. Trials are assessing VISTA inhibitors in a number of cancer types including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian, head and neck cancers and bladder cancer, amongst others. The goal is to assess if blocking VISTA will result in an increase in immune-mediated attack against the tumors, ultimately improving patient survival.

Major Companies Driving VISTA Research & Development

The VISTA therapy domain has been confined to a relatively small group of innovative biopharmaceutical companies. Aurigene Oncology and Curis have been leading players in the sector with their progression of CA-170, the most advanced candidate targeting VISTA used in current clinical trials. Its entry into late-stage development set a benchmark for the increasing confidence in the therapeutic power of VISTA targeting.

Other significant players in the field of VISTA inhibitors are Hummingbird Bioscience, Kineta and PharmAbcine, along with many academic research groups. Hummingbird Bioscience, especially, has generated significant interest with the development of HMBD-002, a first-in-class anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. Strategic alliances, licensing and research collaborations have increasingly become a vital part of many companies development plans, allowing the companies to accelerate their development programs, expand their clinical studies and bolster their immuno-oncology portfolio.

Future Outlook For VISTA Targeting Therapies

The future direction of research in VISTA inhibitor therapies is expected to revolve around a more in depth knowledge of VISTA biology, and determining which patient populations will respond to these therapies. Ongoing research will aim to elucidate VISTA's roles as a novel costimulatory and inhibitory immune checkpoint, as well as a potential predictor of patient response, which may allow for improved patient selection in future studies and therapies.

Beyond oncology indications, research and development efforts are anticipated to continue to broaden the therapeutic application of VISTA-targeted therapies. The role of VISTA modulation in autoimmune and inflammatory diseases is under investigation due to its regulatory function in immunity. Further improvements in biomarker discovery, translational medicine, AI drug discovery, and combination immunotherapy approaches will improve the understanding of this target and offer greater clinical advancement opportunities across diverse indications.

Table of Contents

1. Research Methodology

2. VISTA As Emerging Immune Checkpoint

  • 2.1 What Is VISTA Inhibition?
  • 2.2 Structure & Biology Of VISTA Protein
  • 2.3 Mechanism Of Action Of VISTA Inhibitors

3. VISTA As Inhibitory & Costimulatory Checkpoint

  • 3.1 VISTA As Inhibitory Immune Checkpoint
  • 3.2 VISTA As Costimulatory Checkpoint
  • 3.3 VISTA Inhibition v/s Conventional Immune Checkpoint Inhibitors

4. Significance Of VISTA In Disease Progressiopn & Cure

  • 4.1 Role Of VlSTA In Facilitating Cancer Progression
  • 4.2 VISTA As Potential Cancer Biomarker
  • 4.3 VISTA As Therapeutic Target In Autoimmune Diseases

5. Global VISTA Inhibitors Market & Clinical Development Outlook

  • 5.1 Current Scenario
  • 5.2 Future Opportunities

6. VISTA Targeted Therapies Trends & Clinical Innovation By Indication

  • 6.1 Solid Cancers
  • 6.2 Hematological Cancers
  • 6.3 Autoimmune & Inflammatory Disorders

7. VISTA Targeted Therapies Trends & Clinical Innovation By Region

  • 7.1 US
  • 7.2 Europe
  • 7.3 India
  • 7.4 Australia

8. Global VISTA Inhibitors Clinical Trials Overview

  • 8.1 By Phase
  • 8.2 By Country
  • 8.3 By Indication
  • 8.4 By Organization

9. Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

  • 9.1 Phase I
  • 9.2 Phase I/II
  • 9.3 Phase III

10. Global VISTA Inhibitors Market Dynamics

  • 10.1 Market Drivers
  • 10.2 Market Challenges

11. Competitive Landscape

  • 11.1 Aurigene Discovery Technologies
  • 11.2 Curis
  • 11.3 Hummingbird Bioscience
  • 11.4 Kineta
  • 11.5 PharmAbcine

List of Figures

  • Figure 2-1: VISTA Protein - Structure
  • Figure 2-2: VISTA - Binding Partners
  • Figure 2-3: VISTA Inhibition - Basic Mechanism
  • Figure 3-1: VISTA - Role In Cancer Immunotherapy
  • Figure 3-2: VISTA - Role In Autoimmune Diseases
  • Figure 3-3: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition
  • Figure 4-1: VISTA Interaction With Immune Cells
  • Figure 4-2: VISTA - Mechanisms Of Immune Suppression
  • Figure 4-3: Dual Role Of VISTA In Cancer
  • Figure 4-4: VISTA As Predictive Biomarker
  • Figure 4-5: Autoimmune Diseases - VISTA Agonism
  • Figure 5-1: Future Market Opportunities
  • Figure 6-1: Solid Tumors - VISTA Role In Tumor Immune Evasion
  • Figure 6-2: SNS-101-2-1 Phase 1/2 (NCT05864144) Study - Initiation & Completion Year
  • Figure 6-3: MarkV-01 Phase 1 (NCT05957081) Study - Initiation & Completion Year
  • Figure 6-4: Hematological Cancers - Mechanisms Of Immune Evasion By VISTA
  • Figure 6-5: Autoimmune & Inflammatory Disorders - VISTA As Ligand On APCs
  • Figure 6-6: Autoimmune & Inflammatory Disorders - VISTA As Receptor On T Cells
  • Figure 6-7: Kings College London & Dartmouth College VISTA Patent - Grant & Expiration Year
  • Figure 8-1: Global - Number Of VISTA Inhibitors In Clinical Trials By Phase, 2026
  • Figure 8-2: Global - Number Of VISTA Inhibitors In Clinical Trials By Country, 2026
  • Figure 8-3: Global - Number Of VISTA Inhibitors In Clinical Trials By Indication, 2026
  • Figure 8-4: Global - Number Of VISTA Inhibitors In Clinical Trials By Organization, 2026
  • Figure 10-1: Market Drivers & Opportunities
  • Figure 10-2: Market Challenges & Restraints

List of Tables

  • Table 6-1: VISTA - Role In Autoimmune & Inflammatory Disorders